Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr;10(4):1873–1888. doi: 10.21037/tlcr-21-192

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Translational Lung Cancer Research. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

A 78-year-old male patient who was treated with icotinib and anlotinib developed mass shrinkage and decreased tumor markers. (A) Computed tomographic images from the patient (Table 1, patient no. 4) show the mass before anlotinib treatment, and after 22 months of combination therapy with anlotinib and icotinib, respectively. The red arrows represent the location of the mass in CT images. (B) The time course of CEA concentrations measured in the patient. PR, partial response; SD, stable disease; CEA, carcinoembryonic antigen.